At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
mavacamten +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
In Brief
A Phase 2 clinical trial evaluating mavacamten and Placebo for Non-obstructive Hypertrophic Cardiomyopathy. Completed, enrolled 59 participants across 32 sites.
Detailed Summary
This is a multicenter, exploratory, randomized, double-blind study of the administration of mavacamten in 60 participants with symptomatic nHCM randomized to receive a 16-week course of mavacamten doses titrated to achieve 1 of 2 target drug concentrations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMar 2018
Primary CompletionJan 2020
TodayJul 2026
First PostedFeb 22, 2018
Enrollment StartMar 30, 2018
Primary CompletionJan 7, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.4 years ago
Interventions
mavacamtendrug
MYK-461
Placebodrug
Placebo